Cerus Corporation (NASDAQ:CERS) announced today that it will postpone its scheduled release date for its third quarter financial results from Tuesday, October 30, 2012 to Wednesday, November 7, 2012, after the close of the stock market.
“Given the significant impact Hurricane Sandy has had and is expected to continue to have along the eastern coast of the U.S., we have decided to postpone the release of our third quarter financial results in order to ensure that all members of the investment community have the opportunity to access our results,” said William “Obi” Greenman, Cerus’ president and CEO.
Cerus will host a conference call and webcast accordingly at 4:15 PM EDT on November 7, 2012, during which management will discuss the Company’s financial results and provide a general business overview and outlook.
To access the live webcast, please visit the Investor Relations page of the Cerus web site at
. Alternatively, you may access the live conference call by dialing 866-235-9006 (U.S.) or 631-291-4549 (international).
A replay will be available on the company’s web site, or by dialing 855-859-2056 (U.S.) or 404-537-3406 (international) and entering conference ID number 63119758. The replay will be available approximately three hours after the call through November 21, 2012.
Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action enables INTERCEPT treatment to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. See
for more information.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.